New pharmacy cialis australia online viagradirect.net with a lot of generic and brand medicament with mean price and fast delivery.

Expert4law.org

David Leslie Fogelson
Clinical Professor, University of California at Los Angeles Department of Psychiatry and Biobehavioral Sciences
Education:

University of California at Santa Cruz, honors in Biology
Postdoctoral Training:


Internship and Residencies:


Intern in Medicine, The Faulkner Hospital, Boston, MA Resident in Psychiatry, Tufts University, Court Street Veterans Administration Outpatient Clinic, Boston, MA Resident in Psychiatry, The Neuropsychiatric Institute, Fellow in Psychopharmacology, McLean Hospital, Belmont, Massachusetts, a division of Harvard Medical School Licenses and Certification:
Massachusetts License Registration No. 43088 Diplomate of the National Board of Medical Examiners, Postdoctoral Training:

Licenses and Certification
California License registration No. G039149 Diplomate American Board of Psychiatry and Neurology
Hospital Appointments:

Medical Staff Member, Braintree Hospital, Braintree, MA Psychiatric Staff Member, Boston State Hospital, Boston, MA Psychiatric Staff Member, Olive View Hospital, Los Angeles, CA Psychiatric Staff Member, McLean Hospital, Belmont, MA Medical Staff Member, Encino Hospital, Encino, CA Psychiatric Staff Member, Van Nuys Hospital, Van Nuys, CA Psychiatric Staff Member, Woodview Calabasas Hospital, Psychiatric Staff Member, Westwood Hospital, Westwood, CA Psychiatric Staff Member, St. John’s Hospital, Santa Monica, CA 1981-Present Psychiatric Staff Member, UCLA Neuropsychiatric Hospital,
Awards and Honors:

Graduated with Honors in Biology from the University of Member, Board of Directors, Obsessive Compulsive Foundation Distinguished Fellow American Psychiatric Association Outstanding Junior Clinical Faculty Teaching Award UCLA Neuropsychiatric Institute and Hospital Residency Program Awards and Honors:
Member, Scientific Advisory Board, Obsessive Compulsive Member, Psychiatry Advisory Board, Pfizer Pharmaceuticals Member, Schizophrenia Advisory Board, Pfizer Pharmaceuticals
Major Committee Assignments:

Secretary, Committee on Competency in Psychiatric Residency Training, Neuropsychiatric Institute, University of California at Los Angeles Member, Adult Psychiatric Committee, Woodview Calabasas Chairman, Adult Patient Care Evaluation Committee, Neuropsychiatric Institute, UCLA, Los Angeles, CA Member, Specialty Clinics Committee, Neuropsychiatric Institute, Chairman, Clinical Care Utilization Committee, Neuropsychiatric Institute, UCLA, Los Angeles, CA Member, Medical Records Committee, Neuropsychiatric Institute, Chairman, Pharmacy Committee, Woodview Calabasas Hospital, Chairman, Hospital Psychiatry Committee, Southern California Member, Scientific Program Committee, Southern California Chairman, Health Care Reform Committee, Southern Member, APA Practice Research Network Scientific Advisory Memberships in Professional Societies:

American Association for the Advancement of Science West Coast College of Biological Psychiatry The American Academy of Clinical Psychiatrists Schizophrenia International Research Society
Major Research Interests:

1. The clinical genetics and pathophysiology of Schizophrenia and Schizophrenia Spectrum Disorders; currently medical director of a study of two hundred schizophrenic patients and their first degree relatives as part of a large collaborative research effort. 2. Psychopharmacologic treatment of mood, anxiety and schizophrenic
Teaching Experience:
Supervised clinical work in medicine of Tufts University medical students at Faulkner Hospital Organized Psychopharmacology Seminars for Department of Medicine, Wadsworth Hospital, Los Angeles, CA Supervised clinical work in inpatient psychiatry of UCLA medical students and psychiatry residents, Neuropsychiatric Institute, UCLA, Los Angeles, CA 1982-Present Supervised and lectured psychiatry residents, psychology interns, and medical students, in the outpatient department of the Neuropsychiatric Institute, UCLA, Los Angeles, CA Teaching Experience:
1983-Present Numerous public speaking engagements at hospitals, universities and clinics on various topics in psychopharmacology and the pathophysiology of schizophrenia. International speaker for Pfizer and Bristol-Myers-Squibb; National speaker for Ciba-Geigy, Pfizer, Searle, Lilly, Glaxo-Burroughs-Wellcome, Bristol- Myers Squibb, Wyeth and Abbott Laboratories; regional speaker for Pfizer, Dista, Sandoz Pharmaceuticals, Searle, UpJohn, Bristol- Myers-Squibb, and Mead Johnson; local speaker for Organon, Astra-Zeneca, and Parke-Davis Coordinate and help run anxiety and mood disorders seminars for UCLA psychiatry residents and psychology interns. Chaired an Anxiety Disorders Symposium sponsored by Wyeth 1995-Present Present Advanced Psychopharmacology lectures to UCLA 1996-Present Chaired a journal club for UCLA psychiatry faculty
Principal Clinical and Hospital Service Responsibilities:

Psychiatrist in Charge, Bowditch Hall Clinical Research Unit, Assistant Director, UCLA Outpatient Psychiatry Department, Assistant Director, UCLA Affective Disorders Clinic, Los Angeles,CA Director, Outpatient Psychopharmacology, Neuropsychiatric Director, Anxiety Disorder Treatment Program, Neuropsychiatric 1984-Present Medical Director for the UCLA Family Study of Schizophrenia Director, Intensive Care Unit, Westwood Hospital, Los Angeles, Principal Clinical and Hospital Service Responsibilities:

1988-Present President, Pacific Psychopharmacology Research Institute,
Media Experience:

1982-Present Numerous radio and television interviews Co-wrote and moderated two Art Ulene productions for ABC: “Panic Disorder” and “Obsessive-Compulsive Disorder”. Wrote and moderated two C.M.E. network video productions: “The Pharmacokinetics of Benzodiazepines” and “Panic Disorder” CME Network: “Obsessive Compulsive Disorder” Interview on KTWV radio about the holiday blues and Web-casting, lectures from the UCLA Web studio on psychopharmacology
Reviewer for:
Consultant for American Psychiatric Association Practice Guidelines for the Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry; 2009 Edition. Schizophrenia Research (2007-present) American Journal of Psychiatry (1982-present) Journal of Clinical Psychopharmacology (1988-present) Journal of Neuropsychiatry and Clinical Neurosciences (1996-present) American Psychiatric Association “Practical Guidelines” Series (Fall 1991) Consultant for American Psychiatric Association Practice Guidelines for Eating Disorders, American Journal of Psychiatry, Vol. 150, No. 2, Feb. 1993, p. 207-288
Reviewer for:
Consultant for American Psychiatric Association Practice Guidelines for the Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry 151:12, Dec. 1994 Supplement
Biography:


Journals:

Fogelson, D.L.; Marder, S.R.; Van Putten, T.: “Dialysis for Schizophrenia:
Review of Clinical Trials and Implications for Further Research”, Am J
Psychiatry, 137:605-607, 1980.
Fogelson, D.L.; Cohen, B.M.; Pope, Jr., H.G.: “DSM III Schizophreniform Disorder”, Am J Psychiatry, 139:1281-1285, 1982. Arana, G.W.; Berreira, P.J.; Cohen, B.M.; Lipinski, J.F.; Fogelson, D.L.: “The Dexamethasone Suppression Test in Psychotic Disorders”, Am J Psychiatry, 140:1521-1523, 1983. Nuechterlein, K.H.; Snyder, K.; Dawson, M.; Rappe, S.; Gitlin, M.; Fogelson, D.L.: “Expressed Emotion, Fixed Dose Fluphenazine Treatment, and Relapse in Recent-Onset Schizophrenia”, Psychopharmacology Bulletin, 22(3):633-639, 1986. Gitlin, M.J.; Midha, K.K.; Fogelson, D.L.; Nuechterlein, K.H.: “Persistence of Fluphenazine in Plasma After Decanoate Withdrawal”, J. Clin Psychopharmacol, 8(1):53-56, 1988. Fogelson, D.L.; Bystritsky, A.; Sussman, N.: “Inter-Relationships Between Major Depression and the Anxiety Disorders: Clinical Relevance”, Psychiatric Annals, 18(3):158-167, 1988. Nuechterlein, K.H.; Dawson, M.; Ventura, J.; Fogelson, D.L.; Gitlin, M.; Mintz, J.: “Testing Vulnerability Models: Stability of Potential Vulnerability Indicators Across Clinical State”, In H. Haefner and W.F. Gattaz (Eds.) Search for the Causes of Schizophrenia, Vol. 2. Springer-Verlag Berlin Heidelberg, 1990. Clomipramine Study Group (Fogelson, D.L., member of group): “Clomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder”, Arch Gen Psychiatry, 48(8):730-738, 1991.
Biography:

Journals:
Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Subotnik, K.; Talovic, S.A.:
“Interrater Reliability of the Structured Clinical Interview for DSM-III-R, Axis
II: Schizophrenia Spectrum and Affective Spectrum Disorders”, Psych Research, 39:55-63, 1991. Fogelson, D.L.; Bystritsky, A.: “Imipramine in the Treatment of Obsessive Compulsive Disorder With and Without Major Depression”, Annals of Clin. Psychiatry, 3(3):233-237, 1991. Fogelson, D.L.; Jacobson, S.; Sternbach, H.: “A Retrospective Study of Valproate in Private Practice”, Annals of Clin. Psychiatry, 3(4):315-320, 1991. Fogelson, D.L., Epitome: Obsessive Compulsive Disorder, The Western Journal of Medicine, 155(5):522, 1991. Goldstein, M.J.; Talovic, S.A.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Asarnow, R.F.: “Family Interaction Versus Individual Psychopathology: Do They Indicate the Same Processes in the Families of Schizophrenics?”, British Journal of Psychiatry, Suppl., 161(18):97-102, 1992. Bystritsky, A.; Fogelson, D.L.; Doctor, R.; Yager, J.: “Symptom Differences Among Anxiety Patients in Clinics with Differing Treatment Orientations: A Pilot Investigation”, J. Psychotherapy, 2(2), Spring 1993. Fogelson, D.L.; Bystritsky, A.; Pasnau, R.: “Bupropion in the Treatment of Bipolar Disorders: The Same Old Story?”, J. Clinical Psychiatry, 53:443-446, 1992. Subotnik, K.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Talovic, S.A.: “Depressive Symptoms in the Early Course of Schizophrenia:Relationship to Familial Psychiatric Illness”, Am J Psych, 151(11):1551-1556, 1997. Gitlin, M.; Nuechterlein, K.H.; Mintz, J.; Fogelson, D.L.; Bartzokis, G.; Aravagiri, M.: “Fluphenazine Levels During Maintenance Treatment of Recent Onset Schizophrenia: Relation to Side Effects, Psychosocial Function and Depression”, Psychopharmacology 148:350-354, 2000. Fogelson, D.L., Nuechterlein, K.H.H., Asarnow, R.F.F., Payne, D.L., Subotnik, K.L, Giannini, C.: “The Factor Structure of Schizophrenia Spectrum Signs and Symptoms in First-Degree Relatives of Schizophrenic Patients from the UCLA Family Members Study”, Psychiatry Research 87:137-146, 1999.
Biography:

Journals:
Asarnow, R.F., Nuechterlein, K.H., Fogelson, D.L., Subotnik, K.L., Payne, D.L., Russell, AT., Asamen, J., Kuppinger, H., Kendler, K.S., Schizophrenia and Schizophrenia Spectrum Personality Disorders in the First-Degree Relatives of Children with Schizophrenia: The UCLA Family Members Study, Arch of General Psychiatry, 58:581-588, 2001. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M, Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry, 158(11):1835-42, 2001. Asarnow R, Nuechterlein K, Asamen J, Fogelson DL, Subotnik KL, Zaucha K, Guthrie D: Neurocognitive functioning and schizophrenia spectrum disorders can be independent expressions of familial liability for schizophrenia in community control children: the UCLA family study, Schizophrenia Research. 54:111-120, 2002. Neuchterlein KH, Asarnow RF, Subotnik KL, Fogelson DL, Payne DL, Kendler KS, Neale MC, Jacobson KC, Mintz J: The Structure of Schizotypy: Relationships Between Neurocognitive and Personality Disorder Features in Relatives of Schizophrenic Patients in the UCLA Family Study. Schizophrenia Research, 54:121-130, 2002. Asarnow RF, Nuechterlein KH, Subotnik KL, Fogelson DL, Torquato RD, Payne DL, Asamen J, Mintz J, Guthrie D: Neurocognitive Impairments in Non-psychotic Parents of Children with Schizophrenia and Attention Deficit Disorder: The UCLA Family Study. Arch of General Psychiatry, 59:1053-1060, 2002. Fogelson DL, Nuechterlein KH, Asarnow RF, Payne DL, Subotnik KL. Validity of the family history method for diagnosing schizophrenia, schizophrenia-related psychoses, and schizophrenia-spectrum personality disorders in first-degree relatives of schizophrenia probands. Schizophr Res, 68:309-17, 2004. Subotnik KL, Asarnow RF, Nuechterlein KH, Fogelson DL, Thorpe TI, Payne DL, Giannini CA, Kuppinger HE, Torquato RD, Mintz J, Hwang SS, Gottesman II. MMPI vulnerability indicators for schizophrenia and attention deficit disorder: UCLA family study of biological parents of offspring with childhood-onset schizophrenia or ADHD. Behav Genet., 35(2):159-75, 2005. Fogelson DL, Nuechterlein KH, Asarnow RA, Payne DL, Subotnik KL, Jacobson KC, Neale MC, Kendler KS: Avoidant personality disorder is a separable schizophrenia-spectrum personality disorder even when controlling for the presence of paranoid and schizotypal personality disorders The UCLA family study. Schizophr Res, 91:192-9, 2007. Fogelson DL, Asarnow RA, Sugar CA, Subotnik KL, Jacobson KC, Neale MC, Kendler KS, Kuppinger H, Nuechterlein KH. Avoidant personality disorder symptoms in first-degree relatives of schizophrenia patients predict performance on neurocognitive measures: The UCLA family study. Schizophr Res, 2010 Jan 4, Ahead of Print.
Biography:
Letters:
Fogelson, D.L.: “Using Carbamazepine Effectively”, Am J Psychiatry, 141:1130,
1984.
Fogelson, D.L.: “Lorazepam and Oxazepam in the Treatment of Panic Disorder”.
J. Clin Psychopharmacology, 8(2):150-151,1988.
Fogelson, D.L.: “Weight Gain During Fluoxetine Treatment”, J. Clin Psychopharmacology, 11(3):220, 1991. Fogelson, D.L.: “Nefazodone and/or Sodium Tetradecyl Sulfate Associated Leukopenia, Fever and Shaking Chills in a Patient with Premenstrual Dysphoric Disorder”, J. Clin Psychopharmacology, 17(3):222-223, 1997. Fogelson, D.L.; Sternbach, H.: “Lamotrigine Treatment of Refractory Bipolar Disorder”, J. Clin Psychiatry, 58(6):271-273, 1997. Fogelson, D.L.: “Fenfluramine and the Cytochrome”, P450 System. Am. J. Psychiatry, 154(3):436-437, 1997. Fogelson, D.L.; Sternbach, H.; Payne, D.: “A Naturalistic Pilot Study Comparing Haloperidol, Clozapine, Sertindole, and Risperidone in Partially Responsive Chronic Schizophrenia or Schizoaffective Disorder”, J Clin Psychopharmacology, 17(6):492-494, 1997. Biography:
Abstracts:
Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Mintz, J.: “Depressive Symptoms in Recent-Onset Schizophrenia Patients Are Associated With a Family History of Depression”. Presented at theAmerican Psychiatric Association annual meeting. May 21, 1997, San Diego, CA. Nuechterlein, K.H.; Subotnik, K.L.; Asarnow, R.F.; Gottesman, I.; Fogelson, D.L.; Payne, D.L.; Torquato, R.D.: “MMPI Profiles of First-Degree Relatives of Recent-Onset Schizophrenia Probands”. Presented at the International Congress
Biography:

Abstracts:
Asarnow, R.F.; Nuechterlein, K.H.; Torquato, R.D.; Subotnik, K.L.; Fogelson,D.L.: “Cognitive/Neuropsychological Abnormalities in the Parents of Children with a Schizophrenic Disorder”. Presented at the International Congress on Schizophrenia Research 1997. Subotnik, K.L.; Asarnow, R.F.; Nuechterlein, K.H.; Payne, D.L.; Fogelson, D.L.; Gottesman, I.I.: “MMPI Differences Among First-Degree Relatives of Probands with Childhood-Onset Schizophrenia, Attention Deficit Disorder, and Normal Control Children”. Presented at the International Congress on Schizophrenia Research 1997. Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.L.; Subotnik, K.L.; Giannini, C.: “The Factor Structure of Schizophrenia Spectrum signs and Family Members Study”. Presented at the International Congress on Schizophrenia Research 1997. Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Goldstein, M.J., Fogelson, D.L.; Richard D. Torquato: “Communication Deviance is Associated with Putative Genetic Vulnerability Indicators in Relatives of Schizophrenia Patients”. Presented at the International Congress on Schizophrenia Research, 1999. Fogelson, D.L.; Torquato, R.D.; Asarnow, R.F.; Subotnik, K.L.: “Are Categorical or Dimensional Approaches to Personality Disorders Better for Discriminating the Biological Parents of Probands with Childhood-Onset Schizophrenia Versus ADD”. Presented at the International Congress on Schizophrenia Research, 1999. Nuechterlein, K.H.; Subotnik, K.L.; Gitlin, M.; Dawson, M.E.; Ventura, J.; Snyder, K.S.; Fogelson, D.L.; Shaw, S.; Mintz, J.: “Neurocognitive and Environmental Contributors to Work Recovery After Initial Onset of Schizophrenia: Answers from Path Analyses”. Presented at the International Congress on Schizophrenia Research, 1999. Payne, D.L.; Kuppinger, H.E.; Asarnow, R.F.; Subotnik, K.L.; Fogelson, D.L.; Nuechterlein, K.H.: “Examination of Wisconsin Psychosis-Proneness Scales as an Indication of Familial Vulnerability to Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 1999. Asarnow, R.F.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Torquato, R.D.; Payne, D.L.; Kuppinger, H.E.: “Defining the Boundaries of the Schizophrenia Phenotype: The UCLA Family Study”. Presented at the International Congress on Schizophrenia Research, 1999.
Biography:
Abstracts:
Subotnik, K.L.; Asarnow, R.F.; Fogelson, D.L.; Gottesman, I.I.; Thorpe, T.; Payne, D.L.; Gianninici, C.; Torquato, R.; Kuppinger, H.E.; Nuechterlein, K.H.: “MMPI Vulnerability Indicators for Schizophrenia: Findings from the UCLA Family Study Examining Biological Parents of Children with Schizophrenia or Attention Deficit Disorder and Parents of Community Controls”. Presented at the 2nd International Conference on Early Psychosis March 31, 2000. New York. Asarnow, R.F.; Nuechterlein, K.H.; Subotnik, K.L.; Fogelson, D.L.; Torquato, R.D.; Payne, D.L.; Guthrie, D.: “Specificity of Neurocognitive Impairments in Parents of Probands with Childhood Onset of Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 2001. Subotnik, K.L.; Nuechterlein, K.H.; Gitlin, M.; Siegel, B.; Bartzokis, G.; Fogelson, D.L.; Ventura, J.: “First Episode Patients Treated With Risperidone Show Better Neurocognitive and Functional Outcome Than Patients Treated with Fluphenazine Decanoate”. Presented at the International Congress on Schizophrenia Research, 2001. Nuechterlein, K.H.; Asarnow, R.F.; Jacobson, K.; Subotnik, K.L.; Neale, M.; Fogelson, D.L.; Kendler, K.: “Neurocognitive Vulnerability Factors in First-Degree Relatives of Schizophrenic Probands Show Accelerated Aging Effects”. Presented at the International Congress on Schizophrenia Research, 2001. Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; Gitlin, M.J.; Fogelson, D.L.; Bartzokis, G.; Subotnik, K.L.: “Rates of Smoking in Recent-onset Schizophrenia Patients Receiving Traditional Versus Atypical Antipsychotic Medications”. Presented at the International Congress on Schizophrenia Research, 2001. Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.; Subotnik, K.L.; Kuppinger, H.: “Validity of the Family History Method for Diagnosing Schizophrenia and Schizophrenia related Psychoses in First-Degree Relatives of Schizophrenic Probands”. Presented at the International Congress on Schizophrenia Research, 2001. Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.: “Avoidant Personality Disorder Increases the Detection of First Degree Relatives Affected by a Schizophrenia Spectrum Diagnosis”. Accepted to the International Congress on Schizophrenia Research, 2003. Biography:
Abstracts:
Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Payne, D.L.; Ventura, J.; Kendler, K.S.:”Relationship between positive and negative symptoms of schizophrenia and dimensions of personality pathology in biological parents”. Accepted to the International Congress on Schizophrenia Research, 2003. Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.; Sugar, C.: “Avoidant Personality Disorder Symptoms in First-Degree Relatives of Schizophrenics Predict Performance on Neurocognitive Measures The UCLA Family Study”. Presented at the International Congress on Schizoprhenia Research, 2009 Biography:
Chapters:
Co-author of the Psychiatric Knowledge and Skills Assessment Program - Anxiety Disorders Section, American Psychiatric Association Lenzenweger, M.F. & Dworkin, R.H. (Eds.). (in press). The Pathogenesis of Schizophrenia: An Experimental Psychopathology Perspective. Washington, DC:American Psychological Association. Chapter on: Neurocognitive VulnerabilityFactors for Schizophrenia: Convergence Across Genetic Risk Studies and Longitudinal Trait/State Studies. Nuechterlein, K.H., Asarnow, R.F., Subotnik, K.L., Fogelson, D.L., Ventura, J., Torquato, R.D., Dawson, M.E.
Biography:
Research:
Clinical research trials run at the Pacific Psychopharmacology Research Institute: Anafranil multicenter trial, 1986-1987, Ciba Geigy, for Obsessive Compulsive Buspar multicenter trial, 1987-1988, Mead Johnson, for Xanax withdrawal, phase Tandospirone multicenter trial, 1989-1990, Pfizer, for Panic Disorder, placebo Clinical research trials run at the Pacific Psychopharmacology Research Institute: Tandospirone multicenter trial, 1991-1992, Pfizer for Major Depression, placebo Research:
Ondansetron multicenter trial, 1991, Glaxo, for Generalized Anxiety Disorder, Anafranil multicenter trial, 1991-1993, Ciba Geigy, for Obsessive Compulsive Brofaromine multicenter trial, 1992-1993, Ciba Geigy, for Social Phobia, placebo Fluvoxamine multicenter trial, 1992, Upjohn, for Panic Disorder, placebo Sertindole multicenter trial, 1994, Abbott labs, for Schizophrenia. Lamictal multicenter trial, 1997, Glaxo-Wellcome labs, for Bipolar Depression Aripiprazole multicenter trial, 1998, Otsuka, for Schizophrenia Substance P Antagonist multicenter trial, 1999, Novartis, for Social Phobia. Fluoxetine-Olanzapine multicenter trial, 2000, Eli Lilly for Treatment resistant Depression 193 98 203 multicenter trial, 2000, Otsuka for Major Depression Leviteracetam, multicenter trial, 2003, USB Pharma, Social Phobia

Source: http://www.expert4law.org/ExpertData/david.fogelson_E4LAW_11335481_35228248/23645fogelsonCURRICULUM%20VITAE3.pdf

Microsoft word - eval brief - meds - mar08.doc

EVALUATION BRIEF Medication Use Among Children and Youth Entering the Albany County System of Care LuAnn L. McCormick, PhD, MSW and Kenneth B. Robin, PsyD Center for Human Services Research, University at Albany, State University of New York Introduction The use of medication to treat children’s mental health disorders has increased over the past several decades. There is debate i

Layout

La presenza di versamento pleurico (VP) maligno è una complicanzacomune negli stadi avanzati di varie neoplasie e presenta una inciden-za annuale stimata negli Stati Uniti di circa 150.000 pazienti (1). Inpazienti con tumore del polmone primitivo, il VP si riscontra dal 7% alSino a qualche anno fa la presenza del VP maligno associato ad unaneoplasia polmonare veniva classificata come T4 (sta

Copyright © 2010-2014 Pdf Physician Treatment